Evolving Treatment Paradigm for Relapsed Refractory Multiple Myeloma

home / frontline-forum / evolving-treatment-paradigm-for-relapsed-refractory-multiple-myeloma

In an extension of a meeting of expert faculty from the ASH 2023 conference, Caitlin Costello, MD, and Matthew Pianko, MD, review key data updates on clinical and real-world evidence in multiple myeloma and share insights on how they can be applied to clinical practice for patients with relapsed/refractory multiple myeloma (RRMM).